<DOC>
	<DOCNO>NCT00437203</DOCNO>
	<brief_summary>To determine overall safety PF-00477736 give combination gemcitabine , chemotherapy agent , patient advance solid tumor determine maximum dose PF-00477736 safely give combination gemcitabine . This first study PF-00477736 human .</brief_summary>
	<brief_title>PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine</brief_title>
	<detailed_description>The study close enrollment 17 May 2010 due business reason . The patient study continue treatment 19 April 2011 stop complete response . Premature closure prompt safety efficacy concern .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histological cytopathological diagnosis solid malignancy refractory standard therapy curative therapy exists . ECOG performance status 0 1 . Adequate blood cell count , kidney function liver function . Prior treatment gemcitabine . Uncontrolled brain metastasis , spinal cord compression , carcinomatous meningitis , leptomeningeal disease . NCI CTC Grade 2 high ARDS , noninfectious pneumonitis , pulmonary fibrosis . NCI CTC Grade 2 high cardiovascular toxicity exception NCI CTC Grade 3 hypertension well control . Known human immunodeficiency virus ( HIV ) seropositivity . Concurrent treatment anticoagulant know coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Advanced cancer</keyword>
</DOC>